Familial hypocalciuri hypercalcenia
Reading Document
Medical Text Search
familial hypocalciuric hypercalcemia FHH pathophysiology diagnosis
Medical Text Search
familial hypocalciuric hypercalcemia management treatment differential diagnosis primary hyperparathyroidism
GradeResponse
GradeResponse
Familial Hypocalciuric Hypercalcemia (FHH)
Overview
Familial Hypocalciuric Hypercalcemia (FHH) is a rare, autosomal dominant disorder characterized by lifelong, usually asymptomatic hypercalcemia with paradoxically low urinary calcium excretion. It is critical to distinguish from primary hyperparathyroidism (PHPT), as the management is entirely different.
Pathophysiology
FHH is caused by loss-of-function mutations in the calcium-sensing receptor (CaSR) gene (chromosome 3q). The CaSR is expressed in:
- Parathyroid glands — senses extracellular calcium to regulate PTH secretion
- Renal tubules — regulates urinary calcium excretion
A dysfunctional CaSR raises the "set point" at which calcium suppresses PTH, so higher serum calcium is required to suppress PTH — resulting in hypercalcemia. Simultaneously, renal tubular reabsorption of calcium is enhanced, causing hypocalciuria.
Genetic Subtypes
| Type | Gene | Notes |
|---|---|---|
| FHH1 (most common) | CASR | Loss-of-function CaSR mutation |
| FHH2 | GNA11 | G-protein α-subunit 11 |
| FHH3 | AP2S1 | Adaptor protein 2 sigma subunit; often more severe hypercalcemia |
Clinical Features
FHH is typically benign and asymptomatic. Key features:
- Lifelong mild-to-moderate hypercalcemia (usually 10–12 mg/dL), often detected incidentally
- Hypocalciuria — urine calcium excretion is low despite hypercalcemia
- Detectable in childhood (first decade of life) — a key distinguishing feature from PHPT
- PTH is normal or mildly elevated (inappropriately normal for the degree of hypercalcemia)
- Usually no symptoms of hypercalcemia (no nephrolithiasis, no osteoporosis, no neuromuscular symptoms)
- Positive family history of hypercalcemia in multiple generations
Diagnosis
Key Discriminator: Calcium-to-Creatinine Clearance Ratio (CCCR)
$$\text{CCCR} = \frac{\text{Urine Ca} \times \text{Serum Cr}}{\text{Serum Ca} \times \text{Urine Cr}}$$
| Finding | FHH | Primary Hyperparathyroidism |
|---|---|---|
| CCCR | < 0.01 | > 0.02 |
| Renal Ca reabsorption | > 99% | < 99% |
| PTH | Normal or mildly ↑ | Usually elevated |
| Age at diagnosis | Often < 10 years | Rarely < 10 years |
| Family history | Positive (AD) | Usually absent |
| Symptoms | Absent | Often present |
| Nephrolithiasis | Rare | Common |
According to Harrison's Principles of Internal Medicine (p. 11579): "Most patients with FHH have >99% renal calcium reabsorption," whereas patients with PHPT have <99%.
Confirmatory Testing
- Genetic testing for CASR, GNA11, or AP2S1 mutations — gold standard
- Screen first-degree family members
Distinguishing FHH from Primary Hyperparathyroidism
This is the most clinically important differential, as parathyroid surgery is indicated in PHPT but contraindicated in FHH.
Historical cases of parathyroid surgery performed in FHH patients before the diagnosis was understood resulted in permanent hypoparathyroidism, yet hypocalciuria persisted — confirming that hypocalciuria is intrinsic to the kidney, not a parathyroid effect (Harrison's, p. 11579).
Management
- No treatment required in the vast majority of cases — FHH is a benign, lifelong condition
- Parathyroidectomy is NOT indicated and can be harmful
- Avoid misdiagnosis leading to unnecessary surgery — always calculate CCCR before referring for parathyroid surgery
- Neonatal Severe Hyperparathyroidism (NSHPT): a rare, life-threatening complication in homozygous infants (inheriting two mutant alleles); presents with severe hypercalcemia, bone demineralization, and respiratory distress. These infants do require urgent parathyroidectomy.
- Cinacalcet (a calcimimetic that activates CaSR) has been used in FHH3 and NSHPT with some benefit
Key Takeaways
- FHH = autosomal dominant CaSR loss-of-function → hypercalcemia + hypocalciuria
- CCCR < 0.01 is the key diagnostic clue
- Benign and asymptomatic — no treatment needed
- Do not operate — parathyroid surgery will not correct hypercalcemia and causes permanent hypoparathyroidism
- Genetic testing confirms the diagnosis and guides family screening
Claudin mutation
Medical Text Search
claudin mutation disease familial hypocalciuric hypercalcemia FHH3
Medical Text Search
claudin tight junction renal tubular disorder electrolyte
GradeResponse
GradeResponse
Claudin mutations are distinct from FHH — let me clarify the full picture.
Claudin Mutations and Associated Diseases
Claudins are a family of ~27 proteins that are the principal structural and functional components of tight junctions between epithelial cells. Tight junctions form the paracellular barrier in epithelia, controlling the passage of ions and water between cells. Mutations in claudin genes disrupt this paracellular selectivity, causing specific electrolyte and fluid disorders depending on where that claudin is expressed.
Key Claudin Mutations and Their Diseases
1. CLDN16 (Claudin-16) — Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis (FHHNC)
- Inheritance: Autosomal recessive
- Gene: CLDN16 (formerly called paracellin-1)
- Location of expression: Thick ascending limb (TAL) of the loop of Henle
- Mechanism: Claudin-16 forms paracellular channels for Mg²⁺ and Ca²⁺ reabsorption in the TAL. Loss of function → failure to reabsorb Mg²⁺ and Ca²⁺ paracellularly
- Features:
- Hypomagnesemia
- Hypercalciuria
- Nephrocalcinosis and nephrolithiasis
- Progressive chronic kidney disease (CKD)
- Ocular abnormalities (macular colobomata, nystagmus) in some
- Diagnosis: Low serum Mg²⁺, elevated urine Ca²⁺, nephrocalcinosis on imaging, genetic testing
2. CLDN19 (Claudin-19) — FHHNC with Ocular Involvement
- Inheritance: Autosomal recessive
- Gene: CLDN19
- Location: TAL + retina/eye
- Mechanism: Works in concert with Claudin-16 in the TAL; also expressed in the eye
- Features: Same renal phenotype as CLDN16 mutations (hypomagnesemia, hypercalciuria, nephrocalcinosis), PLUS prominent ocular defects — macular colobomata, myopia, nystagmus
- Key distinction from CLDN16: Severe ocular involvement is the hallmark
3. CLDN14 (Claudin-14) — Autosomal Recessive Deafness (DFNB29)
- Gene: CLDN14
- Location: Organ of Corti (inner ear)
- Features: Non-syndromic sensorineural hearing loss; no renal phenotype
- Note: Polymorphisms in CLDN14 are also associated with hypercalciuria and kidney stones in the general population (GWAS studies)
4. CLDN1 (Claudin-1) — Neonatal Ichthyosis-Sclerosing Cholangitis (NISCH) Syndrome
- Inheritance: Autosomal recessive
- Features:
- Ichthyosis (thickened scaly skin) — skin barrier defect
- Sclerosing cholangitis (liver/biliary)
- Alopecia
5. CLDN11 (Claudin-11) — Deafness and CNS myelin
- Expressed in CNS myelin sheaths and Sertoli cells; mutations associated with hearing loss and male infertility in animal models
Summary Table
| Gene | Disease | Key Features | Inheritance |
|---|---|---|---|
| CLDN16 | FHHNC | Hypomagnesemia, hypercalciuria, nephrocalcinosis, CKD | AR |
| CLDN19 | FHHNC + ocular | As above + macular colobomata, nystagmus | AR |
| CLDN14 | DFNB29 | Sensorineural deafness; also hypercalciuria risk | AR |
| CLDN1 | NISCH syndrome | Ichthyosis, sclerosing cholangitis, alopecia | AR |
Connecting to FHH
In the context of FHH discussed earlier, FHH3 was previously attributed to AP2S1 mutations, not claudin mutations directly. However, claudin-16 and claudin-19 mutations represent the classic "claudin channelopathy" disorders and are the primary clinical entities when "claudin mutation" comes up in the context of renal calcium and magnesium handling.
The FHHNC phenotype (CLDN16/CLDN19) is important to distinguish from FHH:
- FHH → hypocalciuria (calcium is retained)
- FHHNC → hypercalciuria (calcium is wasted) with hypomagnesemia
This is a shared conversation. Sign in to Orris to start your own chat.